此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项关于Lifileucel(肿瘤浸润淋巴细胞)在晚期黑色素瘤成人患者中的研究

2026年9月28日 更新者:Iovance Biotherapeutics, Inc.

一项关于 Lifileucel(肿瘤浸润淋巴细胞 [TIL])在既往接受过治疗的晚期黑色素瘤参与者中进行的 2 期、多中心、开放标签研究

This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma

研究概览

详细说明

This is a Phase 2 study of the lifileucel treatment regimen in participants who previously received treatment for unresectable or metastatic (advanced) melanoma with 1 prior line of an anti-programmed cell death protein-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) agent or whose melanoma progressed during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (early relapse). Participants who have BRAF V600 mutation positive melanoma may have received or refused 1 additional prior line treatment with a BRAF inhibitor

± a MEK inhibitor

研究类型

介入性

注册 (估计的)

24

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ontario, Canada
      • Toronto、Ontario, Canada、加拿大、M5G 2M9
        • Princess Margaret Cancer Centre
    • Quebec, Canada
      • Montral、Quebec, Canada、加拿大、H2X 0A9
        • Centre Hospitalier de l'Universite de Montreal
    • Queensland
      • Greenslopes、Queensland、澳大利亚、4120
        • Greenslopes Private Hospital
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • Sarah Cannon Research Institute
      • London、英国、SW3 6JJ
        • Royal Marsden Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma.
  • The participant has an ECOG performance status of 0 or 1 and an estimated life expectancy of > 6 months.
  • The participant must have experienced radiographic disease progression on: 1 prior line of an anti-PD-(L)1 treatment (as a monotherapy or as part of a combination) for advanced melanoma or during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (as a monotherapy or as part of a combination). Participants who have BRAF V600 mutation positive melanoma may have received 1 additional prior line of treatment with a BRAF inhibitor ± a MEK inhibitor or choose lifileucel as an alternative option to a BRAF inhibitor ± a MEK inhibitor.
  • Participant is assessed as having at least one resectable lesion (or aggregate lesions) for lifileucel generation.
  • Participant must have at least one measurable disease as defined by RECIST 1.1 following tumor resection.
  • Participants who are > 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
  • Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
  • Participants must have adequate organ function.
  • Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.

Exclusion Criteria:

  • Participant has melanoma of uveal/ocular origin.
  • Participant has symptomatic untreated brain metastases.
  • Participant has active uveitis that requires active treatment.
  • Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation, such as systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.
  • Participant has any form of primary or acquired immunodeficiency (eg, SCID or AIDS).
  • Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or were curatively treated >1 year ago, and in the judgment of the investigator do not pose a significant risk of recurrence.)
  • Participant has a history of allogeneic cell or organ transplant.
  • Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.

Other protocol defined inclusion/exclusion criteria could apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Single Arm

Lifileucel

A tumor sample is resected from each patient for lifileucel manufacturing. Patients will first receive the preparative non-myeloablative lymphodepletion (NMA-LD) regimen. They will then receive the lifileucel infusion, followed by an abbreviated course of aldesleukin.

其他名称:
  • LN-144

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Objective Response Rate
大体时间:12 months

To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the investigators

12 months

次要结果测量

结果测量
措施说明
大体时间
Complete Response Rate
大体时间:12 months

To evaluate the efficacy of lifileucel as measured by CR rate per RECIST v1.1 as assessed by the investigators

12 months
Duration of Response
大体时间:12 months

To evaluate the efficacy of lifileucel as measured by DOR per RECIST v1.1 as assessed by the investigators

12 months
Disease Control Rate
大体时间:12 months

To evaluate the efficacy of lifileucel as measured by DCR per RECIST v1.1 as assessed by the investigators

12 months
Progression-Free Survival
大体时间:12 months

To evaluate the efficacy of lifileucel as measured by PFS per RECIST v1.1 as assessed by the investigators

12 months
Overall Survival
大体时间:18 months

To evaluate the efficacy of lifileucel as measured by OS

18 months
Adverse Events
大体时间:18 months

To demonstrate safety and tolerability of lifileucel

18 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年11月28日

初级完成 (估计的)

2027年12月1日

研究完成 (估计的)

2028年6月1日

研究注册日期

首次提交

2025年12月9日

首先提交符合 QC 标准的

2025年12月15日

首次发布 (实际的)

2025年12月17日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅